Keywords: aventis, growth, driven, strong, pharmaceutical, sales, franco-german
Aventis growth driven by strong US pharmaceutical sales
Article | 06 November 2001
Franco-German group Aventis reports that net income for the first ninemonths of 2001 reached 1.12 billion euros ($1.01 billion), compared with 463 million euros ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
